Prostate‐specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma
File version
Author(s)
Yang, Ian A
Godbolt, David B
Windsor, Morgan N
Henderson, Daniel
Kyle, Samuel
Sterling, David
Lee, Joseph C
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Prostate‐specific membrane antigen (PSMA) is a type II transmembrane glycoprotein encoded by the folate hydrolase 1 (FOLH1) gene. The enzyme is overexpressed in prostate cancer cells.1 A recent systematic review showed 68Ga‐labelled PSMA–positron emission tomography (PET) as having a sensitivity of 66% and specificity of 99% for primary lymph node metastases in high‐risk prostate cancer patients.2 PSMA‐PET is also positive in renal cell carcinoma, hepatocellular carcinoma, non‐small cell lung cancer, squamous cell (lung and other), gynaecological and colorectal malignancies.3-7
Journal Title
ANZ Journal of Surgery
Conference Title
Book Title
Edition
Volume
89
Issue
9
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Surgery
CANCER
Persistent link to this record
Citation
Ekanayake, SKDM; Yang, IA; Godbolt, DB; Windsor, MN; Henderson, D; Kyle, S; Sterling, D; Lee, JC, Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma., ANZ Journal of Surgery, 2019, 89 (9), pp. E406-E407